ecancermedicalscience

Special Issue

Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

21 Nov 2023
Benjamín Walbaum, José Miguel Reyes, Pablo Rodriguez, Sabrina Muñiz, Lidia Medina, Carolina Ibáñez, Tomás Merino, Mauricio P Pinto, Maria Loreto Bravo, Francisco Acevedo, José Bennett, Cesar Sánchez

Background: The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting.

Methods: Our retrospective population-cohort study included HR+/HER2- ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors.

Results: A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib (p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS.

Conclusion: Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2- ABC patients.

Related Articles

Ademola Oluwatosin Oyekan, Omolara Aminat Fatiregun, Muhammad Habeebu, Ifeanyichukwu Augustine Onyeodi, Adebayo Deborah Adeoluwa
Gustavo Hipólito Diaz Infantes, Edgar Fermín Yan Quiroz, Luis Fernando Meza Montoya, José Richard Tenazoa Villalobos
Omolara Aminat Fatiregun, Yetunde Kuyinu, Adewunmi Alabi, Anthonia Sowunmi, Okunuga Ndidi, Popoola O Abiodun, Temitope Olatunji-Agunbiade, Oyekan Ademola, Nnodimele Onuigbo Atulomah, Awotayo Olajumoke
Anass Baladi, Mohammed El Fadli, Hassan Abdelilah Tafenzi, Kawtar El Bouaouidi, Nada Benhima, Leila Afani, Ismail Essâdi, Rhizlane Belbaraka
Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem